Antimicrobial coated breakaway variable lumen connector for intravenous therapy
About ARCHER
IV therapy is the most performed invasive treatment received by about 90% of in-hospital patients[1]. However, more than 40% of the treatments are disrupted by a premature IV catheter failure resulting from mechanical complications[2]. This leads to drugs and plastic waste, increased costs, unsafe work environment and patient injury. These problems also increase the risk for Catheter Related Blood Stream Infections (CRBSIs) which are a leading cause of morbidity and mortality among hospitalized patients.
Together Interlinked AB and Amicoat AS aim to develop AM-ReLink as a device family of self-sterilising safety connectors to simultaneously prevent IV catheter failure and CRBSIs in patients. AM-ReLink can reduce the introduction of bacteria into the bloodstream that results in serious infections, increased healthcare costs and decreases the instances of IV catheter failure.
About AM-ReLink
AM-ReLink is a highly novel self-cleaning breakaway connector for IV therapy. Our connector consists of two reconnectable parts with double safety valves, to be placed between the IV tube and the catheter, using the standard Luer-Lock fitting. The safety valves and all other surfaces of the connector in contact with the IV fluid will be impregnated with antimicrobial coating technology based on synthetic mimetics of antimicrobial peptides (AMPs). These integrated components constitute an attractive and unique product for the IV therapy market.
Interlinked AB
Interlinked is dedicated to advancing safety in IV therapy and nephrostomy drainage by preventing catheter dislodgement. Our flagship platform, ReLink, is a breakaway connector designed to reduce catheter dislodgement and minimise fluid and blood spills. By reducing these complications, ReLink promotes patient and nurse safety, minimises the risk of toxic exposure, alleviates the burden of care at bedside, and enables accurate drug delivery. ReLink drives radically superior care outcomes.
Amicoat AS
Amicoat is a Norwegian biotechnology company that discovers, develops, and commercializes novel antimicrobial science with broad applications across diverse industries. Their primary product, AMC-109, offers a reliable and environmentally safe antimicrobial solution addressing needs across a wide range of industries. AMC-109 is backed by extensive data demonstrating efficacy and safety and inducing antimicrobial activity with minimal environmental impact.
News
The project has received funding from the Eurostars-2 joint Programme with co-funding from the European Union's Horizon 2020 research and innovation programme.
References
-
Corrigan, A. "Infusion nursing as a specialty." Infusion Nursing: An Evidence-Based Approach. 3rd ed. St Louis, MO: Saunders/Elsevier 4 (2010): 5.
-
Literature study data